EGFR and neoplasm: Uptake was partly EGFR specific, as demonstrated by significantly lower tumor uptake upon co-injection of unlabeled cetuximab (4.76 ± 0.3%IA/g versus 2.94 ± 0.79%IA/g, p = 0.0201).